SCISPARC: SUBSIDIARY NEUROTHERA LABS PURSUES FDA ORPHAN DRUG DESIGNATION FOR ADULT TOURETTE SYNDROME DRUG; ENGAGES GOVERNMENT AND PUBLIC AFFAIRS FIRM RK STRATEGIES

Reuters · 3d ago

Please log in to view news